筋強直性ジストロフィー治療のグローバル市場インサイト・予測（～2027年）

• 英文タイトル：Global Myotonic Dystrophy Therapeutics Market Insights and Forecast to 2027

• レポートコード：QY2112C03891 • 出版社/出版日：QYResearch / 2021年12月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査資料は筋強直性ジストロフィー治療の世界市場の現状について調査・分析し、2027年までの市場を予測しました。筋強直性ジストロフィー治療の世界市場概要、メーカー別の競争状況と市場シェア、種類別市場規模（ナトリウムチャネル遮断薬、三環系抗うつ薬、その他）、用途別市場規模（病院薬局、小売薬局、その他）、主要地域別市場規模（北米・アメリカ、ヨーロッパ、アジア・日本・中国・インド、中南米、中東・アフリカ）、関連企業の情報、バリューチェーン・販売チャネル、市場動向などを収録しています。 ・筋強直性ジストロフィー治療の世界市場概要 ・メーカー別の競争状況、市場シェア ・筋強直性ジストロフィー治療の種類別市場規模：ナトリウムチャネル遮断薬、三環系抗うつ薬、その他 ・筋強直性ジストロフィー治療の用途別市場規模：病院薬局、小売薬局、その他 ・北米の筋強直性ジストロフィー治療市場規模2016-2027：種類別、用途別、国別（アメリカ、カナダ） ・ヨーロッパの筋強直性ジストロフィー治療市場規模2016-2027：種類別、用途別、国別（ドイツ、フランス、イギリス） ・アジアの筋強直性ジストロフィー治療市場規模2016-2027：種類別、用途別、国別（日本、中国、インド、韓国） ・中南米の筋強直性ジストロフィー治療市場規模2016-2027：種類別、用途別、国別（メキシコ、ブラジル） ・中東・アフリカの筋強直性ジストロフィー治療市場規模2016-2027：種類別、用途別、国別（トルコ、サウジアラビア） ・企業情報：Lupin、Teva、ANI Pharmaceuticals、Mylan、Novartis、Sun Pharma、Mallinckrodt ・筋強直性ジストロフィー治療のバリューチェーン・販売チャネル分析 ・筋強直性ジストロフィー治療の世界市場動向

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.

Market Analysis and Insights: Global Myotonic Dystrophy Therapeutics Market
The global Myotonic Dystrophy Therapeutics market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.

Global Myotonic Dystrophy Therapeutics Scope and Segment
Myotonic Dystrophy Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myotonic Dystrophy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Sodium Channel Blocker
Tricyclic Antidepressant
Other

Segment by Application
Hospital Pharmacy
Retail Pharmacy
Other

By Company
Lupin
Teva
ANI Pharmaceuticals
Mylan
Novartis
Sun Pharma
Mallinckrodt

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Myotonic Dystrophy Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global Myotonic Dystrophy Therapeutics Market Size Growth Rate by Type
1.2.2 Sodium Channel Blocker
1.2.3 Tricyclic Antidepressant
1.2.4 Other
1.3 Market by Application
1.3.1 Global Myotonic Dystrophy Therapeutics Market Size Growth Rate by Application
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Myotonic Dystrophy Therapeutics Sales Estimates and Forecasts 2016-2027
2.2 Global Myotonic Dystrophy Therapeutics Revenue Estimates and Forecasts 2016-2027
2.3 Global Myotonic Dystrophy Therapeutics Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Myotonic Dystrophy Therapeutics Regions by Sales
2.4.1 Global Top Myotonic Dystrophy Therapeutics Regions by Sales (2016-2021)
2.4.2 Global Top Myotonic Dystrophy Therapeutics Regions by Sales (2022-2027)
2.5 Global Top Myotonic Dystrophy Therapeutics Regions by Revenue
2.5.1 Global Top Myotonic Dystrophy Therapeutics Regions by Revenue (2016-2021)
2.5.2 Global Top Myotonic Dystrophy Therapeutics Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa

3 Competition by Manufacturers
3.1 Global Myotonic Dystrophy Therapeutics Sales by Manufacturers
3.1.1 Global Top Myotonic Dystrophy Therapeutics Manufacturers by Sales (2016-2021)
3.1.2 Global Top Myotonic Dystrophy Therapeutics Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Therapeutics Sales in 2020
3.2 Global Myotonic Dystrophy Therapeutics Revenue by Manufacturers
3.2.1 Global Top Myotonic Dystrophy Therapeutics Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Myotonic Dystrophy Therapeutics Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Therapeutics Revenue in 2020
3.3 Global Myotonic Dystrophy Therapeutics Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Myotonic Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Myotonic Dystrophy Therapeutics Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Myotonic Dystrophy Therapeutics Sales by Type
4.1.1 Global Myotonic Dystrophy Therapeutics Historical Sales by Type (2016-2021)
4.1.2 Global Myotonic Dystrophy Therapeutics Forecasted Sales by Type (2022-2027)
4.1.3 Global Myotonic Dystrophy Therapeutics Sales Market Share by Type (2016-2027)
4.2 Global Myotonic Dystrophy Therapeutics Revenue by Type
4.2.1 Global Myotonic Dystrophy Therapeutics Historical Revenue by Type (2016-2021)
4.2.2 Global Myotonic Dystrophy Therapeutics Forecasted Revenue by Type (2022-2027)
4.2.3 Global Myotonic Dystrophy Therapeutics Revenue Market Share by Type (2016-2027)
4.3 Global Myotonic Dystrophy Therapeutics Price by Type
4.3.1 Global Myotonic Dystrophy Therapeutics Price by Type (2016-2021)
4.3.2 Global Myotonic Dystrophy Therapeutics Price Forecast by Type (2022-2027)

5 Market Size by Application
5.1 Global Myotonic Dystrophy Therapeutics Sales by Application
5.1.1 Global Myotonic Dystrophy Therapeutics Historical Sales by Application (2016-2021)
5.1.2 Global Myotonic Dystrophy Therapeutics Forecasted Sales by Application (2022-2027)
5.1.3 Global Myotonic Dystrophy Therapeutics Sales Market Share by Application (2016-2027)
5.2 Global Myotonic Dystrophy Therapeutics Revenue by Application
5.2.1 Global Myotonic Dystrophy Therapeutics Historical Revenue by Application (2016-2021)
5.2.2 Global Myotonic Dystrophy Therapeutics Forecasted Revenue by Application (2022-2027)
5.2.3 Global Myotonic Dystrophy Therapeutics Revenue Market Share by Application (2016-2027)
5.3 Global Myotonic Dystrophy Therapeutics Price by Application
5.3.1 Global Myotonic Dystrophy Therapeutics Price by Application (2016-2021)
5.3.2 Global Myotonic Dystrophy Therapeutics Price Forecast by Application (2022-2027)

6 North America
6.1 North America Myotonic Dystrophy Therapeutics Market Size by Type
6.1.1 North America Myotonic Dystrophy Therapeutics Sales by Type (2016-2027)
6.1.2 North America Myotonic Dystrophy Therapeutics Revenue by Type (2016-2027)
6.2 North America Myotonic Dystrophy Therapeutics Market Size by Application
6.2.1 North America Myotonic Dystrophy Therapeutics Sales by Application (2016-2027)
6.2.2 North America Myotonic Dystrophy Therapeutics Revenue by Application (2016-2027)
6.3 North America Myotonic Dystrophy Therapeutics Market Size by Country
6.3.1 North America Myotonic Dystrophy Therapeutics Sales by Country (2016-2027)
6.3.2 North America Myotonic Dystrophy Therapeutics Revenue by Country (2016-2027)
6.3.3 United States
6.3.4 Canada

7 Europe
7.1 Europe Myotonic Dystrophy Therapeutics Market Size by Type
7.1.1 Europe Myotonic Dystrophy Therapeutics Sales by Type (2016-2027)
7.1.2 Europe Myotonic Dystrophy Therapeutics Revenue by Type (2016-2027)
7.2 Europe Myotonic Dystrophy Therapeutics Market Size by Application
7.2.1 Europe Myotonic Dystrophy Therapeutics Sales by Application (2016-2027)
7.2.2 Europe Myotonic Dystrophy Therapeutics Revenue by Application (2016-2027)
7.3 Europe Myotonic Dystrophy Therapeutics Market Size by Country
7.3.1 Europe Myotonic Dystrophy Therapeutics Sales by Country (2016-2027)
7.3.2 Europe Myotonic Dystrophy Therapeutics Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia

8 Asia Pacific
8.1 Asia Pacific Myotonic Dystrophy Therapeutics Market Size by Type
8.1.1 Asia Pacific Myotonic Dystrophy Therapeutics Sales by Type (2016-2027)
8.1.2 Asia Pacific Myotonic Dystrophy Therapeutics Revenue by Type (2016-2027)
8.2 Asia Pacific Myotonic Dystrophy Therapeutics Market Size by Application
8.2.1 Asia Pacific Myotonic Dystrophy Therapeutics Sales by Application (2016-2027)
8.2.2 Asia Pacific Myotonic Dystrophy Therapeutics Revenue by Application (2016-2027)
8.3 Asia Pacific Myotonic Dystrophy Therapeutics Market Size by Region
8.3.1 Asia Pacific Myotonic Dystrophy Therapeutics Sales by Region (2016-2027)
8.3.2 Asia Pacific Myotonic Dystrophy Therapeutics Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia

9 Latin America
9.1 Latin America Myotonic Dystrophy Therapeutics Market Size by Type
9.1.1 Latin America Myotonic Dystrophy Therapeutics Sales by Type (2016-2027)
9.1.2 Latin America Myotonic Dystrophy Therapeutics Revenue by Type (2016-2027)
9.2 Latin America Myotonic Dystrophy Therapeutics Market Size by Application
9.2.1 Latin America Myotonic Dystrophy Therapeutics Sales by Application (2016-2027)
9.2.2 Latin America Myotonic Dystrophy Therapeutics Revenue by Application (2016-2027)
9.3 Latin America Myotonic Dystrophy Therapeutics Market Size by Country
9.3.1 Latin America Myotonic Dystrophy Therapeutics Sales by Country (2016-2027)
9.3.2 Latin America Myotonic Dystrophy Therapeutics Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia

10 Middle East and Africa
10.1 Middle East and Africa Myotonic Dystrophy Therapeutics Market Size by Type
10.1.1 Middle East and Africa Myotonic Dystrophy Therapeutics Sales by Type (2016-2027)
10.1.2 Middle East and Africa Myotonic Dystrophy Therapeutics Revenue by Type (2016-2027)
10.2 Middle East and Africa Myotonic Dystrophy Therapeutics Market Size by Application
10.2.1 Middle East and Africa Myotonic Dystrophy Therapeutics Sales by Application (2016-2027)
10.2.2 Middle East and Africa Myotonic Dystrophy Therapeutics Revenue by Application (2016-2027)
10.3 Middle East and Africa Myotonic Dystrophy Therapeutics Market Size by Country
10.3.1 Middle East and Africa Myotonic Dystrophy Therapeutics Sales by Country (2016-2027)
10.3.2 Middle East and Africa Myotonic Dystrophy Therapeutics Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia

11 Company Profiles
11.1 Lupin
11.1.1 Lupin Corporation Information
11.1.2 Lupin Overview
11.1.3 Lupin Myotonic Dystrophy Therapeutics Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Lupin Myotonic Dystrophy Therapeutics Product Description
11.1.5 Lupin Recent Developments
11.2 Teva
11.2.1 Teva Corporation Information
11.2.2 Teva Overview
11.2.3 Teva Myotonic Dystrophy Therapeutics Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Teva Myotonic Dystrophy Therapeutics Product Description
11.2.5 Teva Recent Developments
11.3 ANI Pharmaceuticals
11.3.1 ANI Pharmaceuticals Corporation Information
11.3.2 ANI Pharmaceuticals Overview
11.3.3 ANI Pharmaceuticals Myotonic Dystrophy Therapeutics Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 ANI Pharmaceuticals Myotonic Dystrophy Therapeutics Product Description
11.3.5 ANI Pharmaceuticals Recent Developments
11.4 Mylan
11.4.1 Mylan Corporation Information
11.4.2 Mylan Overview
11.4.3 Mylan Myotonic Dystrophy Therapeutics Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Mylan Myotonic Dystrophy Therapeutics Product Description
11.4.5 Mylan Recent Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Overview
11.5.3 Novartis Myotonic Dystrophy Therapeutics Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Novartis Myotonic Dystrophy Therapeutics Product Description
11.5.5 Novartis Recent Developments
11.6 Sun Pharma
11.6.1 Sun Pharma Corporation Information
11.6.2 Sun Pharma Overview
11.6.3 Sun Pharma Myotonic Dystrophy Therapeutics Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Sun Pharma Myotonic Dystrophy Therapeutics Product Description
11.6.5 Sun Pharma Recent Developments
11.7 Mallinckrodt
11.7.1 Mallinckrodt Corporation Information
11.7.2 Mallinckrodt Overview
11.7.3 Mallinckrodt Myotonic Dystrophy Therapeutics Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Mallinckrodt Myotonic Dystrophy Therapeutics Product Description
11.7.5 Mallinckrodt Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 Myotonic Dystrophy Therapeutics Value Chain Analysis
12.2 Myotonic Dystrophy Therapeutics Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Myotonic Dystrophy Therapeutics Production Mode & Process
12.4 Myotonic Dystrophy Therapeutics Sales and Marketing
12.4.1 Myotonic Dystrophy Therapeutics Sales Channels
12.4.2 Myotonic Dystrophy Therapeutics Distributors
12.5 Myotonic Dystrophy Therapeutics Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Myotonic Dystrophy Therapeutics Industry Trends
13.2 Myotonic Dystrophy Therapeutics Market Drivers
13.3 Myotonic Dystrophy Therapeutics Market Challenges
13.4 Myotonic Dystrophy Therapeutics Market Restraints

14 Key Findings in The Global Myotonic Dystrophy Therapeutics Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Myotonic Dystrophy Therapeutics Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Sodium Channel Blocker
Table 3. Major Manufacturers of Tricyclic Antidepressant
Table 4. Major Manufacturers of Other
Table 5. Global Myotonic Dystrophy Therapeutics Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 6. Global Myotonic Dystrophy Therapeutics Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 7. Global Myotonic Dystrophy Therapeutics Sales by Region (2016-2021) & (K Units)
Table 8. Global Myotonic Dystrophy Therapeutics Sales Market Share by Region (2016-2021)
Table 9. Global Myotonic Dystrophy Therapeutics Sales by Region (2022-2027) & (K Units)
Table 10. Global Myotonic Dystrophy Therapeutics Sales Market Share by Region (2022-2027)
Table 11. Global Myotonic Dystrophy Therapeutics Revenue by Region (2016-2021) & (US$ Million)
Table 12. Global Myotonic Dystrophy Therapeutics Revenue Market Share by Region (2016-2021)
Table 13. Global Myotonic Dystrophy Therapeutics Revenue by Region (2022-2027) & (US$ Million)
Table 14. Global Myotonic Dystrophy Therapeutics Revenue Market Share by Region (2022-2027)
Table 15. Global Myotonic Dystrophy Therapeutics Sales by Manufacturers (2016-2021) & (K Units)
Table 16. Global Myotonic Dystrophy Therapeutics Sales Share by Manufacturers (2016-2021)
Table 17. Global Myotonic Dystrophy Therapeutics Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 18. Global Myotonic Dystrophy Therapeutics Revenue Share by Manufacturers (2016-2021)
Table 19. Myotonic Dystrophy Therapeutics Price by Manufacturers 2016-2021 (US$/Unit)
Table 20. Global Myotonic Dystrophy Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Myotonic Dystrophy Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Therapeutics as of 2020)
Table 22. Myotonic Dystrophy Therapeutics Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Myotonic Dystrophy Therapeutics Product Offered
Table 24. Date of Manufacturers Enter into Myotonic Dystrophy Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Myotonic Dystrophy Therapeutics Sales by Type (2016-2021) & (K Units)
Table 27. Global Myotonic Dystrophy Therapeutics Sales by Type (2022-2027) & (K Units)
Table 28. Global Myotonic Dystrophy Therapeutics Sales Share by Type (2016-2021)
Table 29. Global Myotonic Dystrophy Therapeutics Sales Share by Type (2022-2027)
Table 30. Global Myotonic Dystrophy Therapeutics Revenue by Type (2016-2021) & (US$ Million)
Table 31. Global Myotonic Dystrophy Therapeutics Revenue by Type (2022-2027) & (US$ Million)
Table 32. Global Myotonic Dystrophy Therapeutics Revenue Share by Type (2016-2021)
Table 33. Global Myotonic Dystrophy Therapeutics Revenue Share by Type (2022-2027)
Table 34. Myotonic Dystrophy Therapeutics Price by Type (2016-2021) & (US$/Unit)
Table 35. Global Myotonic Dystrophy Therapeutics Price Forecast by Type (2022-2027) & (US$/Unit)
Table 36. Global Myotonic Dystrophy Therapeutics Sales by Application (2016-2021) & (K Units)
Table 37. Global Myotonic Dystrophy Therapeutics Sales by Application (2022-2027) & (K Units)
Table 38. Global Myotonic Dystrophy Therapeutics Sales Share by Application (2016-2021)
Table 39. Global Myotonic Dystrophy Therapeutics Sales Share by Application (2022-2027)
Table 40. Global Myotonic Dystrophy Therapeutics Revenue by Application (2016-2021) & (US$ Million)
Table 41. Global Myotonic Dystrophy Therapeutics Revenue by Application (2022-2027) & (US$ Million)
Table 42. Global Myotonic Dystrophy Therapeutics Revenue Share by Application (2016-2021)
Table 43. Global Myotonic Dystrophy Therapeutics Revenue Share by Application (2022-2027)
Table 44. Myotonic Dystrophy Therapeutics Price by Application (2016-2021) & (US$/Unit)
Table 45. Global Myotonic Dystrophy Therapeutics Price Forecast by Application (2022-2027) & (US$/Unit)
Table 46. North America Myotonic Dystrophy Therapeutics Sales by Type (2016-2021) & (K Units)
Table 47. North America Myotonic Dystrophy Therapeutics Sales by Type (2022-2027) & (K Units)
Table 48. North America Myotonic Dystrophy Therapeutics Revenue by Type (2016-2021) & (US$ Million)
Table 49. North America Myotonic Dystrophy Therapeutics Revenue by Type (2022-2027) & (US$ Million)
Table 50. North America Myotonic Dystrophy Therapeutics Sales by Application (2016-2021) & (K Units)
Table 51. North America Myotonic Dystrophy Therapeutics Sales by Application (2022-2027) & (K Units)
Table 52. North America Myotonic Dystrophy Therapeutics Revenue by Application (2016-2021) & (US$ Million)
Table 53. North America Myotonic Dystrophy Therapeutics Revenue by Application (2022-2027) & (US$ Million)
Table 54. North America Myotonic Dystrophy Therapeutics Sales by Country (2016-2021) & (K Units)
Table 55. North America Myotonic Dystrophy Therapeutics Sales by Country (2022-2027) & (K Units)
Table 56. North America Myotonic Dystrophy Therapeutics Revenue by Country (2016-2021) & (US$ Million)
Table 57. North America Myotonic Dystrophy Therapeutics Revenue by Country (2022-2027) & (US$ Million)
Table 58. Europe Myotonic Dystrophy Therapeutics Sales by Type (2016-2021) & (K Units)
Table 59. Europe Myotonic Dystrophy Therapeutics Sales by Type (2022-2027) & (K Units)
Table 60. Europe Myotonic Dystrophy Therapeutics Revenue by Type (2016-2021) & (US$ Million)
Table 61. Europe Myotonic Dystrophy Therapeutics Revenue by Type (2022-2027) & (US$ Million)
Table 62. Europe Myotonic Dystrophy Therapeutics Sales by Application (2016-2021) & (K Units)
Table 63. Europe Myotonic Dystrophy Therapeutics Sales by Application (2022-2027) & (K Units)
Table 64. Europe Myotonic Dystrophy Therapeutics Revenue by Application (2016-2021) & (US$ Million)
Table 65. Europe Myotonic Dystrophy Therapeutics Revenue by Application (2022-2027) & (US$ Million)
Table 66. Europe Myotonic Dystrophy Therapeutics Sales by Country (2016-2021) & (K Units)
Table 67. Europe Myotonic Dystrophy Therapeutics Sales by Country (2022-2027) & (K Units)
Table 68. Europe Myotonic Dystrophy Therapeutics Revenue by Country (2016-2021) & (US$ Million)
Table 69. Europe Myotonic Dystrophy Therapeutics Revenue by Country (2022-2027) & (US$ Million)
Table 70. Asia Pacific Myotonic Dystrophy Therapeutics Sales by Type (2016-2021) & (K Units)
Table 71. Asia Pacific Myotonic Dystrophy Therapeutics Sales by Type (2022-2027) & (K Units)
Table 72. Asia Pacific Myotonic Dystrophy Therapeutics Revenue by Type (2016-2021) & (US$ Million)
Table 73. Asia Pacific Myotonic Dystrophy Therapeutics Revenue by Type (2022-2027) & (US$ Million)
Table 74. Asia Pacific Myotonic Dystrophy Therapeutics Sales by Application (2016-2021) & (K Units)
Table 75. Asia Pacific Myotonic Dystrophy Therapeutics Sales by Application (2022-2027) & (K Units)
Table 76. Asia Pacific Myotonic Dystrophy Therapeutics Revenue by Application (2016-2021) & (US$ Million)
Table 77. Asia Pacific Myotonic Dystrophy Therapeutics Revenue by Application (2022-2027) & (US$ Million)
Table 78. Asia Pacific Myotonic Dystrophy Therapeutics Sales by Region (2016-2021) & (K Units)
Table 79. Asia Pacific Myotonic Dystrophy Therapeutics Sales by Region (2022-2027) & (K Units)
Table 80. Asia Pacific Myotonic Dystrophy Therapeutics Revenue by Region (2016-2021) & (US$ Million)
Table 81. Asia Pacific Myotonic Dystrophy Therapeutics Revenue by Region (2022-2027) & (US$ Million)
Table 82. Latin America Myotonic Dystrophy Therapeutics Sales by Type (2016-2021) & (K Units)
Table 83. Latin America Myotonic Dystrophy Therapeutics Sales by Type (2022-2027) & (K Units)
Table 84. Latin America Myotonic Dystrophy Therapeutics Revenue by Type (2016-2021) & (US$ Million)
Table 85. Latin America Myotonic Dystrophy Therapeutics Revenue by Type (2022-2027) & (US$ Million)
Table 86. Latin America Myotonic Dystrophy Therapeutics Sales by Application (2016-2021) & (K Units)
Table 87. Latin America Myotonic Dystrophy Therapeutics Sales by Application (2022-2027) & (K Units)
Table 88. Latin America Myotonic Dystrophy Therapeutics Revenue by Application (2016-2021) & (US$ Million)
Table 89. Latin America Myotonic Dystrophy Therapeutics Revenue by Application (2022-2027) & (US$ Million)
Table 90. Latin America Myotonic Dystrophy Therapeutics Sales by Country (2016-2021) & (K Units)
Table 91. Latin America Myotonic Dystrophy Therapeutics Sales by Country (2022-2027) & (K Units)
Table 92. Latin America Myotonic Dystrophy Therapeutics Revenue by Country (2016-2021) & (US$ Million)
Table 93. Latin America Myotonic Dystrophy Therapeutics Revenue by Country (2022-2027) & (US$ Million)
Table 94. Middle East and Africa Myotonic Dystrophy Therapeutics Sales by Type (2016-2021) & (K Units)
Table 95. Middle East and Africa Myotonic Dystrophy Therapeutics Sales by Type (2022-2027) & (K Units)
Table 96. Middle East and Africa Myotonic Dystrophy Therapeutics Revenue by Type (2016-2021) & (US$ Million)
Table 97. Middle East and Africa Myotonic Dystrophy Therapeutics Revenue by Type (2022-2027) & (US$ Million)
Table 98. Middle East and Africa Myotonic Dystrophy Therapeutics Sales by Application (2016-2021) & (K Units)
Table 99. Middle East and Africa Myotonic Dystrophy Therapeutics Sales by Application (2022-2027) & (K Units)
Table 100. Middle East and Africa Myotonic Dystrophy Therapeutics Revenue by Application (2016-2021) & (US$ Million)
Table 101. Middle East and Africa Myotonic Dystrophy Therapeutics Revenue by Application (2022-2027) & (US$ Million)
Table 102. Middle East and Africa Myotonic Dystrophy Therapeutics Sales by Country (2016-2021) & (K Units)
Table 103. Middle East and Africa Myotonic Dystrophy Therapeutics Sales by Country (2022-2027) & (K Units)
Table 104. Middle East and Africa Myotonic Dystrophy Therapeutics Revenue by Country (2016-2021) & (US$ Million)
Table 105. Middle East and Africa Myotonic Dystrophy Therapeutics Revenue by Country (2022-2027) & (US$ Million)
Table 106. Lupin Corporation Information
Table 107. Lupin Description and Major Businesses
Table 108. Lupin Myotonic Dystrophy Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 109. Lupin Myotonic Dystrophy Therapeutics Product
Table 110. Lupin Recent Developments
Table 111. Teva Corporation Information
Table 112. Teva Description and Major Businesses
Table 113. Teva Myotonic Dystrophy Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 114. Teva Myotonic Dystrophy Therapeutics Product
Table 115. Teva Recent Developments
Table 116. ANI Pharmaceuticals Corporation Information
Table 117. ANI Pharmaceuticals Description and Major Businesses
Table 118. ANI Pharmaceuticals Myotonic Dystrophy Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 119. ANI Pharmaceuticals Myotonic Dystrophy Therapeutics Product
Table 120. ANI Pharmaceuticals Recent Developments
Table 121. Mylan Corporation Information
Table 122. Mylan Description and Major Businesses
Table 123. Mylan Myotonic Dystrophy Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 124. Mylan Myotonic Dystrophy Therapeutics Product
Table 125. Mylan Recent Developments
Table 126. Novartis Corporation Information
Table 127. Novartis Description and Major Businesses
Table 128. Novartis Myotonic Dystrophy Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 129. Novartis Myotonic Dystrophy Therapeutics Product
Table 130. Novartis Recent Developments
Table 131. Sun Pharma Corporation Information
Table 132. Sun Pharma Description and Major Businesses
Table 133. Sun Pharma Myotonic Dystrophy Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 134. Sun Pharma Myotonic Dystrophy Therapeutics Product
Table 135. Sun Pharma Recent Developments
Table 136. Mallinckrodt Corporation Information
Table 137. Mallinckrodt Description and Major Businesses
Table 138. Mallinckrodt Myotonic Dystrophy Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 139. Mallinckrodt Myotonic Dystrophy Therapeutics Product
Table 140. Mallinckrodt Recent Developments
Table 141. Key Raw Materials Lists
Table 142. Raw Materials Key Suppliers Lists
Table 143. Myotonic Dystrophy Therapeutics Distributors List
Table 144. Myotonic Dystrophy Therapeutics Customers List
Table 145. Myotonic Dystrophy Therapeutics Market Trends
Table 146. Myotonic Dystrophy Therapeutics Market Drivers
Table 147. Myotonic Dystrophy Therapeutics Market Challenges
Table 148. Myotonic Dystrophy Therapeutics Market Restraints
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Myotonic Dystrophy Therapeutics Product Picture
Figure 2. Global Myotonic Dystrophy Therapeutics Market Share by Type in 2020 & 2027
Figure 3. Sodium Channel Blocker Product Picture
Figure 4. Tricyclic Antidepressant Product Picture
Figure 5. Other Product Picture
Figure 6. Global Myotonic Dystrophy Therapeutics Market Share by Application in 2020 & 2027
Figure 7. Hospital Pharmacy
Figure 8. Retail Pharmacy
Figure 9. Other
Figure 10. Myotonic Dystrophy Therapeutics Report Years Considered
Figure 11. Global Myotonic Dystrophy Therapeutics Sales 2016-2027 (K Units)
Figure 12. Global Myotonic Dystrophy Therapeutics Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Myotonic Dystrophy Therapeutics Revenue 2016-2027 (US$ Million)
Figure 14. Global Myotonic Dystrophy Therapeutics Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 15. Global Myotonic Dystrophy Therapeutics Sales Market Share by Region (2016-2021)
Figure 16. Global Myotonic Dystrophy Therapeutics Sales Market Share by Region (2022-2027)
Figure 17. North America Myotonic Dystrophy Therapeutics Sales YoY (2016-2027) & (K Units)
Figure 18. North America Myotonic Dystrophy Therapeutics Revenue YoY (2016-2027) & (US$ Million)
Figure 19. Europe Myotonic Dystrophy Therapeutics Sales YoY (2016-2027) & (K Units)
Figure 20. Europe Myotonic Dystrophy Therapeutics Revenue YoY (2016-2027) & (US$ Million)
Figure 21. Asia-Pacific Myotonic Dystrophy Therapeutics Sales YoY (2016-2027) & (K Units)
Figure 22. Asia-Pacific Myotonic Dystrophy Therapeutics Revenue YoY (2016-2027) & (US$ Million)
Figure 23. Latin America Myotonic Dystrophy Therapeutics Sales YoY (2016-2027) & (K Units)
Figure 24. Latin America Myotonic Dystrophy Therapeutics Revenue YoY (2016-2027) & (US$ Million)
Figure 25. Middle East & Africa Myotonic Dystrophy Therapeutics Sales YoY (2016-2027) & (K Units)
Figure 26. Middle East & Africa Myotonic Dystrophy Therapeutics Revenue YoY (2016-2027) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Myotonic Dystrophy Therapeutics Sales in 2020
Figure 28. The Top 10 and Top 5 Players Market Share by Myotonic Dystrophy Therapeutics Revenue in 2020
Figure 29. Myotonic Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 30. Global Myotonic Dystrophy Therapeutics Sales Market Share by Type (2016-2027)
Figure 31. Global Myotonic Dystrophy Therapeutics Revenue Market Share by Type (2016-2027)
Figure 32. Global Myotonic Dystrophy Therapeutics Sales Market Share by Application (2016-2027)
Figure 33. Global Myotonic Dystrophy Therapeutics Revenue Market Share by Application (2016-2027)
Figure 34. North America Myotonic Dystrophy Therapeutics Sales Market Share by Type (2016-2027)
Figure 35. North America Myotonic Dystrophy Therapeutics Revenue Market Share by Type (2016-2027)
Figure 36. North America Myotonic Dystrophy Therapeutics Sales Market Share by Application (2016-2027)
Figure 37. North America Myotonic Dystrophy Therapeutics Revenue Market Share by Application (2016-2027)
Figure 38. North America Myotonic Dystrophy Therapeutics Sales Share by Country (2016-2027)
Figure 39. North America Myotonic Dystrophy Therapeutics Revenue Share by Country (2016-2027)
Figure 40. United States Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 41. Canada Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 42. Europe Myotonic Dystrophy Therapeutics Sales Market Share by Type (2016-2027)
Figure 43. Europe Myotonic Dystrophy Therapeutics Revenue Market Share by Type (2016-2027)
Figure 44. Europe Myotonic Dystrophy Therapeutics Sales Market Share by Application (2016-2027)
Figure 45. Europe Myotonic Dystrophy Therapeutics Revenue Market Share by Application (2016-2027)
Figure 46. Europe Myotonic Dystrophy Therapeutics Sales Share by Country (2016-2027)
Figure 47. Europe Myotonic Dystrophy Therapeutics Revenue Share by Country (2016-2027)
Figure 48. Germany Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 49. France Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 50. U.K. Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 51. Italy Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 52. Russia Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 53. Asia Pacific Myotonic Dystrophy Therapeutics Sales Market Share by Type (2016-2027)
Figure 54. Asia Pacific Myotonic Dystrophy Therapeutics Revenue Market Share by Type (2016-2027)
Figure 55. Asia Pacific Myotonic Dystrophy Therapeutics Sales Market Share by Application (2016-2027)
Figure 56. Asia Pacific Myotonic Dystrophy Therapeutics Revenue Market Share by Application (2016-2027)
Figure 57. Asia Pacific Myotonic Dystrophy Therapeutics Sales Share by Region (2016-2027)
Figure 58. Asia Pacific Myotonic Dystrophy Therapeutics Revenue Share by Region (2016-2027)
Figure 59. China Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 60. Japan Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 61. South Korea Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 62. India Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 63. Australia Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 64. China Taiwan Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 65. Indonesia Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 66. Thailand Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 67. Malaysia Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 68. Latin America Myotonic Dystrophy Therapeutics Sales Market Share by Type (2016-2027)
Figure 69. Latin America Myotonic Dystrophy Therapeutics Revenue Market Share by Type (2016-2027)
Figure 70. Latin America Myotonic Dystrophy Therapeutics Sales Market Share by Application (2016-2027)
Figure 71. Latin America Myotonic Dystrophy Therapeutics Revenue Market Share by Application (2016-2027)
Figure 72. Latin America Myotonic Dystrophy Therapeutics Sales Share by Country (2016-2027)
Figure 73. Latin America Myotonic Dystrophy Therapeutics Revenue Share by Country (2016-2027)
Figure 74. Mexico Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 75. Brazil Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 76. Argentina Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 77. Colombia Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 78. Middle East and Africa Myotonic Dystrophy Therapeutics Sales Market Share by Type (2016-2027)
Figure 79. Middle East and Africa Myotonic Dystrophy Therapeutics Revenue Market Share by Type (2016-2027)
Figure 80. Middle East and Africa Myotonic Dystrophy Therapeutics Sales Market Share by Application (2016-2027)
Figure 81. Middle East and Africa Myotonic Dystrophy Therapeutics Revenue Market Share by Application (2016-2027)
Figure 82. Middle East and Africa Myotonic Dystrophy Therapeutics Sales Share by Country (2016-2027)
Figure 83. Middle East and Africa Myotonic Dystrophy Therapeutics Revenue Share by Country (2016-2027)
Figure 84. Turkey Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 85. Saudi Arabia Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 86. UAE Myotonic Dystrophy Therapeutics Revenue (2016-2027) & (US$ Million)
Figure 87. Myotonic Dystrophy Therapeutics Value Chain
Figure 88. Myotonic Dystrophy Therapeutics Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed

---